VSTM·Verastem, Inc.

On session 7 the tracked gain rose 2.13 points to 15.67%, while the latest capture edged 0.20% lower to $10.04 but remained just above VWAP. The 20-session Healthcare lead is still 24.69 points; that relative strength supports the market side, but early VS-7375 response rates still lack duration, patient counts and fuller safety detail.

The tracked VSTM gain increased only 0.12 points to 13.54% on session 7. Shares slipped 1.84% to $9.88 but remained above VWAP on 0.76 times usual volume, while the 20-session Healthcare lead is 22.82 points. Strong relative performance persists, but early VS-7375 response rates do not establish duration or patient counts; the prepared packet leaves that clinical confirmation open.

The tracked gain dropped 2.48 points to 13.42% on session 7 as shares eased to $9.99 below the session average on very light activity. Its 20-session lead over Healthcare grew to 23.63 points, preserving relative strength, but the reported early VS-7375 response still lacks duration, patient counts and safety detail; the November 5 results date supplies a checkpoint, not an outcome.

The tracked gain grew 1.50 points to 15.90% on session 6 as shares rose 9.23% to $10.06 above VWAP near the high on 1.91 times average volume. The 20-session lead over Healthcare widened to 22.24 points. The November 5 results date adds a checkpoint but no new clinical outcome, so the strong tape does not settle durability.

Verastem scheduled Q3 results and a business update for November 5, adding a dated checkpoint but no new clinical outcome. On session 6, VSTM's tracked gain widened 8.29 points to 14.40%; shares rose 7.60% to $9.91, above VWAP near the session high on 1.49 times average volume. Its 20-session Healthcare lead reached 20.14 points and price remains above $7.45. The model gives only 40.1% same-direction probability through session 15, with a near-flat median and a wide range, so it does not explain the strong tape or settle clinical durability.

VSTM narrowed its tracked gain by 1.49 points to +6.11% on session 5. The latest quote fell 1.39% to $9.21; the available VWAP read was 2.67% below, near the range low, with time-adjusted activity easing. Its twenty-session lead over Healthcare remains 6.58 points, but this pullback does not resolve early VS-7375 response duration and safety or the dilution from the $250 million offering.

VSTM's tracked gain held at 7.60% on session 5; shares rose 8.35% to $9.34 and finished 1.43% above VWAP, while time-adjusted activity was only 0.29. The initial VS-7375 response data remain early, with duration and safety unresolved, and the $250 million offering at $8 adds dilution; the strong tape improves follow-through but does not establish clinical validation.

VSTM’s tracked return rose 8.29 points to +7.60% on session 4; shares gained 7.60% to $9.28 and held 1.43% above VWAP, with time-adjusted activity at 0.29. Verastem’s Oct. 14 update reported a 41% confirmed response rate (9/22) in 2L+ pancreatic cancer after median follow-up of 6.4 months; the phase 1/2 results remain early. The company priced a $250m offering at $8 per share to support development and general needs, increasing dilution. The rebound improves the tape while clinical validation remains unresolved.

VSTM's tracked result fell 1.84 percentage points, turning a 1.15% gain into a 0.69% loss, while shares slipped 0.35% but stayed 1.01% above VWAP on 1.11 times average volume. Price is just below the .66 reference; the earlier 6.16-point Healthcare lead is the last complete comparison, and early response data still do not establish durability or safety.

VSTM's tracked return improved 1.50 points to a 1.15% gain as the quote rose 1.91%, held 0.97% above VWAP and traded at 0.79 times normal volume; it remains above the $7.45 reference. Its 20-session lead over Healthcare is 6.16 points, but the initial VS-7375 response data still lack evidence here on duration, patient counts and safety.

VSTM's tracked return fell 1.04 points to a 0.35% loss after a 6.28% decline on 2.03 times normal volume, closing 1.86% below VWAP near the lower range. It still leads Healthcare by 11.32 points over 20 sessions and remains above 7.45, so the published boundary holds; this sharp retracement weakens the market response while the early clinical data remain untested for durability.

VSTM tracked gain fell 3.69 points to 0.69%; the latest quote dropped 5.04% and sits 1.85% below the session average price weighted by volume. The current price remains above the original $7.45 reference and its 20-session lead over Healthcare is 12.94 points, so the market case weakened without crossing the published price boundary; the initial response data are still early.

VSTM's tracked gain fell 1.96 points to 4.38%, and the quote dropped 4.93%, 1.01% below VWAP. Its 20-session lead over Healthcare remains 12.31 points, but today's reversal weakens the event response; the initial VS-7375 summary still omits patient counts, response duration and safety detail, so approval or commercial value remains unestablished.

VSTM's tracked return edged up 0.12 percentage points to 6.34% after another strong quote gain of 19.71% on 6.1 times average volume; post-market trading slipped 0.87%. High participation sustains the market reaction, but the initial VS-7375 response data still lack patient counts, response duration and safety detail. Those early findings do not establish approval or commercial value.

VSTM's tracked return improved 14.28 points to a 6.22% gain as shares rose 20.62% in the late-session capture, held 5.56% above their volume-weighted average, and traded 4.67 times normal volume; its 20-session Healthcare lead widened to 17.75 points. The market case strengthened, but the initial VS-7375 response data still lack patient counts, duration and safety detail, while a near-even, wide model range does not settle continuation.

VSTM's tracked loss narrowed 3.12 points to 8.06% as shares rose 5.84% in the early capture, 1.81% above VWAP near the top of the range; it outperformed SPY by 6.17 points, and its 20-session lead over Healthcare widened to 1.98 points. Price remains above the $7.45 reference, but initial VS-7375 response rates still lack patient counts, response duration and safety detail; the model's near-even, broad range leaves follow-through unresolved.

VSTM tracked loss widened 2.77 points to 11.18%; shares rose 3.49% in the regular session and another 2.72% after hours, but remained 6.20% below VWAP. The 20-session lead over Healthcare is 1.64 points. The initial VS-7375 response rates remain early evidence without patient counts, response duration, or safety detail; the price rebound does not supply those missing clinical facts.

Since publication, VSTM's tracked return stands at -8.41%; the quote has faded from +16.22% at the initial capture to +6.24% versus the $7.45 prior close, and now sits 3.71% below VWAP. Today's volume is 13.67 times its average and the 20-session Healthcare lead is 4.98 points, while the initial clinical response rates still lack patient counts, duration and safety detail. No session-15 estimate is available yet.